US-based virtual women’s healthcare company Allara has raised $30m in new funding to expand its insurance-covered care model, enterprise partnerships and AI-enabled clinical services.
The round brings the company’s total funding to $75m, with existing investors Index Ventures and GV increasing their commitments. New investors include Camino Partners, Foreground Capital and Family Fund.
Founded by Rachel Blank, Allara provides virtual care for hormonal, metabolic and reproductive health conditions, pairing women’s health clinicians with registered dieticians to deliver ongoing medical treatment and nutritional support.
Rather than relying solely on direct patient payments, Allara works with major US insurers to cover eligible medical and nutrition consultations. Its care model combines specialist appointments, laboratory testing, medication management and personalised lifestyle support within a single platform.
The company has served more than 120,000 women across the US, including patients with PMOS, thyroid disorders, fertility concerns and metabolic conditions, as well as those navigating postpartum and perimenopause.
“We’ve proven at scale that integrated, insurance-covered care can produce meaningful outcomes for women,” said Rachel.
“Our next phase is about making that care dramatically more accessible. With broad insurance coverage, new distribution partnerships and technology that helps our care teams operate at scale, we have an opportunity to reach millions of women.”
The latest investment will support Allara’s next phase of growth, with a focus on expanding distribution through employers, healthcare providers and other strategic partners.
Allara already offers in-network access through major insurers in most US states. The company plans to build on these relationships and its existing clinical infrastructure to reach a wider patient population.
Expanding services and investing in AI
Allara has continued to broaden its clinical offering beyond its original focus on hormonal and metabolic conditions.
This year, the company expanded access to treatments including GLP-1 medications, supported by nutrition and lifestyle guidance, hormone replacement therapy, prescription skincare and hair loss medications.
It has also introduced virtual urgent care for conditions including bacterial vaginosis, urinary tract infections and sexually transmitted infection testing.
The expanded offering is intended to allow Allara to address a wider range of women’s health needs through a single care platform.
The company has also reported outcomes from its existing patient population. In a patient survey, 89% of respondents said they felt supported in making positive changes to their health, while 78% reported positive changes to their diet. Among those experiencing irregular menstrual cycles, 69% reported improvements in cycle regularity.
Among patients with obesity who had received care for at least six months, 73% lost weight, with 48% losing at least 5% of their body weight and 28% losing 10% or more, according to company data.
The new funding will also support further development of Allara’s proprietary AI technology.
The company is already using AI for clinical chart synthesis, decision support and provider assistance, and plans to introduce patient-facing AI tools within its app.
Allara says the technology is designed to increase clinical capacity and support patient outcomes while keeping healthcare professionals at the centre of care.
“Allara is delivering an exceptional care experience for women whose complex needs have fallen through cracks in the traditional healthcare system,” said Elle Lanning, president at Camino Partners.
“Rachel and her team have built an approach that meets women where they are, takes their conditions seriously, and consistently delivers outcomes through a unique multidisciplinary care model.”